To access this element change to forms mode OFF
Grant Award View - GA214892
Developing FXIIa inhibitors as next-generation anticoagulants
GA ID:
GA214892
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
21-Nov-2021
Publish Date:
24-Jan-2022
Category:
Health and Medical Research
Grant Term:
1-Jan-2022 to 31-Jan-2024
Value (AUD):
$706,196.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 20/21 1.1 Health and Medical Research
Grant Program:
Development Grants
Grant Activity:
Developing FXIIa inhibitors as next-generation anticoagulants
Purpose:
We have designed a new potential drug to inhibit disease-related blood clotting without interfering with normal clotting processes. The new molecule is promising because it is effective at stopping clotting, but to develop it into a drug we need to generate additional data confirming its safety and stability, then test it in animal models of thrombosis as a precursor to human trials. This project aims to generate these data and to optimise the lead molecule to make it suitable for such trials.
GO ID:
GO Title:
NHMRC Development Grants 2021 for funding in 2022
Internal Reference ID:
2021/GNT2014512
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The University of Queensland
Recipient ABN:
63 942 912 684
Grant Recipient Location
Suburb:
St Lucia
Town/City:
St Lucia
Postcode:
4072
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
QLD
Postcode:
Country:
AUSTRALIA